ÂÜÀòÂÒÂ×

Andrew Chi has a strong background in clinical development and oncology research. Andrew is currently working as the Vice President of Clinical Development at Bright Peak Therapeutics, a position they have held since October 2021. Prior to this role, they served as the Senior Editor of Clinical Cancer Research at the American Association for Cancer Research starting in January 2017. From December 2019 to September 2021, they worked as the Executive Medical Director at Mirati Therapeutics. Andrew also held positions at Neon Therapeutics, NYU Langone Health, Harvard Medical School and Massachusetts General Hospital, Broad Institute of MIT and Harvard, and Dana-Farber Cancer Institute. These roles involved various responsibilities in neuro-oncology research, clinical fellowships, and directorship in translational neuro-oncology.

Andrew Chi has a MD, PhD in Biochemistry and Molecular Biology from the Chicago Medical School at Rosalind Franklin U-Med & Science. Andrew was an intern at Harvard Medical School, specializing in Medicine. Following this, they completed their residency and served as the Chief Resident in Neurology at Harvard Medical School.